Compare Abbott Laboratories (ABT) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs L3Harris Technologies Inc — how do they compare? Abbott Laboratories trades at $94.92 (market cap $166.94B), while L3Harris Technologies Inc trades at $293.12 (market cap $55.03B). The key difference: Abbott Laboratories is far larger — about 3× L3Harris Technologies Inc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | LHX | |
|---|---|---|
Market Cap | $166.94B | $55.03B |
Sector | Health | Industrials |
52-Week High | $136.62 | $378.48 |
52-Week Low | $82.57 | $257.09 |
Enterprise Value | $193.69B | $65.80B |
Dividend Yield | 2.63% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
LHX trades at $295.4, down 2.21% today, with a bullish technical signal despite near-term overbought RSI conditions. The company reported strong Q1 2026 earnings, beating estimates with $5.7B revenue and a 1.4x book-to-bill ratio, boosting its backlog to a record $40.7B. Recent news highlights expansion in missile production and new defense contracts, supporting growth momentum.
LHX presents a favorable outlook with robust defense sector tailwinds and consistent earnings beats, though elevated valuation metrics and geopolitical risks warrant caution. Analyst consensus is strongly bullish with a $367.50 price target, implying significant upside from current levels if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
